Paul G. Montgomery, M.D. - Hematology/Oncology

Dr. Montgomery is a medical oncologist with the Mountain States Tumor Institute at St. Luke's Regional Medical Center in Boise. He is a Clinical Instructor for the University of Washington in Seattle

American Board of Internal Medicine - 1988

Subspecialty Certification in Hematology (ABIM) - 1990

Subspecialty Certification in Oncology (ABIM) - 1991

Prostate Cancer

M.D.: University of Washington Medical School, Seattle, 1985

Internal Medicine Residency, Mayo Clinic, Rochester, MN, 1985 - 1988

Hematology Fellowship, Mayo Clinic, Rochester, MN, 1988 - 1990

Oncology Fellowship, Mayo Clinic, Rochester, MN, 1990 - 1991

Clinical Instructor in Medicine, University of Washington, Seattle, 1993 - present

Idaho Elks Rehabilitation Hospital, Boise

Memorial Hospital, Weiser, ID

Saint Alphonsus Regional Medical Center, Boise

St. Luke's Regional Medical Center, Boise

Veterans Administration Medical Center, Boise

Twin Falls Clinic and Hospital, Twin Falls, ID

Magic Valley Clinic and Hospital, Twin Falls, ID

Fellow, American College of Physicians

American Society of Clinical Oncology

American Society of Hematology

1. Kamel OW, van de Rijn M, Weiss LM, et al. (1993). Reversible lymphomas associated with Epstein-Barr Virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. New England Journal of Medicine 328(18): 1317 - 1321.
2. Weaver CH, Bensinger WI, Applebaum FR, et al. (1994). Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplantation 14: 813 - 819.
3. Bensinger QI, Schiffman KS, Holmberg L, et al. (1997). High-dose busulfan, melphalan, thiotepa, and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplantation 19: 1183 - 1189.
4. Bensinger W, Applebaum F, Rowley S, et al. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 13: 2547 - 2555.

No financial report received from reviewer.